Establishment Labs (NASDAQ:ESTA) Given Buy Rating at TD Cowen

Establishment Labs (NASDAQ:ESTA)‘s stock had its “buy” rating reissued by research analysts at TD Cowen in a research report issued on Thursday, MarketBeat.com reports. They presently have a $117.00 price objective on the stock. TD Cowen’s price objective points to a potential upside of 90.68% from the stock’s current price.

ESTA has been the topic of a number of other research reports. Needham & Company LLC boosted their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a research note on Thursday, August 13th. BTIG Research reaffirmed a “buy” rating and set a $103.00 target price on shares of Establishment Labs in a research note on Tuesday, September 1st. JPMorgan Chase & Co. boosted their target price on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $98.56.

Establishment Labs Price Performance

Shares of NASDAQ ESTA traded up $3.48 during midday trading on Thursday, reaching $61.36. 484,364 shares of the company were exchanged, compared to its average volume of 514,968. The stock’s 50-day moving average price is $70.01 and its 200-day moving average price is $74.43. The stock has a market cap of $1.83 billion, a P/E ratio of -46.84 and a beta of 1.06. Establishment Labs has a one year low of $44.26 and a one year high of $97.59. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The company had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. The business’s quarterly revenue was up 31.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.57) EPS. On average, sell-side analysts anticipate that Establishment Labs will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

Several institutional investors have recently modified their holdings of ESTA. State of Alaska Department of Revenue bought a new stake in shares of Establishment Labs in the third quarter worth $80,000. Engineers Gate Manager LP grew its stake in shares of Establishment Labs by 7.5% in the second quarter. Engineers Gate Manager LP now owns 31,458 shares of the company’s stock worth $2,699,000 after purchasing an additional 2,191 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Establishment Labs during the second quarter valued at $32,000. NewEdge Advisors LLC boosted its position in Establishment Labs by 34.9% during the second quarter. NewEdge Advisors LLC now owns 13,871 shares of the company’s stock valued at $1,190,000 after acquiring an additional 3,587 shares during the last quarter. Finally, Arizona State Retirement System boosted its position in Establishment Labs by 5.6% during the second quarter. Arizona State Retirement System now owns 5,057 shares of the company’s stock valued at $434,000 after acquiring an additional 268 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc (NASDAQ: ESTA) is a medical technology company focused on women’s health and breast aesthetics. The company develops, manufactures and markets medical devices intended for breast augmentation, reconstruction and related procedures.

Its principal product portfolio includes Motiva breast implants, a line of silicone-gel implants designed for aesthetic and reconstructive applications, as well as tissue expanders and other products used in breast surgery. Establishment Labs also offers Mia Femtech, a technology and procedure platform designed to support a less invasive approach to breast augmentation.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves healthcare providers and patients in international markets.